Data on novel IL-1 inhibitor protein for topical treatment of dry eye disease published

Preclinical data showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases, were published in PNAS. Eleven Biotherapeutics, Howard Hughes Medical Institute and Stanford University School of Medicine describe how EBI-005 was designed to specifically bind more tightly to its target than IL-1Ra, providing a dramatic increase in potency in vivo. EBI-005 also showed substantially greater stability, potentially provid…

Fuente : http://www.eurekalert.org/pub_releases/2013-02/tyn…